% | $
Quotes you view appear here for quick access.

Regenerx Biopharmaceuticals Inc. Message Board

  • sdhoolteach2000 sdhoolteach2000 Jun 18, 2013 5:11 PM Flag

    Avon et al

    You have got to be kidding, but maybe not.

    After reading the claims of Avon's patent application, I became excited. If RGRX has a patent for skin care using TB-4, it won't be long before many whose, who companies will come knocking at the door. EsteLauder, Revlon, Clinque etc.

    One could conjecture that this is the reason for the band aids and if EB gets the nod from the FDA it would cause a stampede to buy the stock.


    Sentiment: Hold

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Don't get excited. The brass ring possibly for RGRX and TB 4 is EB....NOT skin/wrinkle care. FYI? TB 4 is flushed down toilet for other skin indications if they ever get approval for TB 4 in EB. As an ORPHAN drug, TB 4 in EB would get around $20,000 to $30,000 a year for pts who need it. TB 4 for basic wrinkle creme would get $30 to $50 a jar - at retail. All other indications for TB 4 in skin (pressure ulcers, venous ulcers) are flushed down toilet. You cannot charge TB4 $30,000 for EB pts (insurance paid)...and $50 a small jar for wrinkles.... I suppose they could do TB 4 "fragments" for cosmetics....but again, the revenue they get for TB 4 in EB as Orphan drug will negate possibility of most other VERY cheaper applications in skin. Insurance companies woudl scream bloody murder.....

      • 1 Reply to snogreen
      • In addition to our four pharmaceutical product candidates, we are also pursuing the commercial development of peptide fragments and derivatives of Tß4 for potential cosmeceutical use. These fragments are amino acid sequences, and variations thereof, within the Tß4 molecule that have demonstrated activity in several in vitro preclinical research studies that we have sponsored. We believe the biological activities of these fragments may be useful, for example, in developing novel cosmeceutical products for the anti-aging market. Our strategy is to collaborate with another company to develop cosmeceutical formulations based on these peptides

0.3846-0.0054(-1.38%)Jul 25 3:49 PMEDT